Sirolimus-eluting coronary stents: A review

Vascular Health and Risk Management

Volumn 3, Issue 2, 2007, Pages 191-201

  Abizaid, Alexandre ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

Angioplasty; Percutaneous coronary intervention; Rapamycin; Restenosis; Sirolimus eluting stent

Indexed keywords

CYCLOSPORIN A; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; ANEURYSM; BALLOON DILATATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GRAFT OCCLUSION; HEART DISEASE; HEART MUSCLE NECROSIS; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; INCIDENCE; INTERMETHOD COMPARISON; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; REVIEW; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

BLOOD VESSEL PROSTHESIS IMPLANTATION; CLINICAL TRIALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 34249854140     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2007.3.2.191     Document Type: Review

References (64)

1. Alfonso F, Perez-Vazcayno MJ, Hernandez R, et al. 2006. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol, 47:2152-60.
2. Aoki J, Ong A, Rodriguez Granillo GA, et al. 2005. "Full metal jacket" (stented length >r = 64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J, 150:994-9.
3. Ardissino D, Cavallini C, Bramucci E, et al. 2004. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA, 292:2727-34.
4. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. 2005. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol, 95:1469-72.
5. Chakraborty TK, Weber HP, Nicolaou KC. 1995. Design and synthesis of a rapamycin-based high affinity binding FKBR12 ligand. Chem Biol Mar, 2:157-61.
6. Chang JY, Sehgal SN, Bansbach CC. 1991. FK506 and rapamycin novel pharmacological probes of the immune response. Trends Pharmacol Sci, 12:218-23.
7. Colombo A, Corbett SJ. 2006. Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized. J Am Coll Cardiol, 48:203-5.
8. Dibra A, Kastrati A, Mehilli J, et al. 2005. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med, 353:663-70.
9. Gallo R, Padurean A, Jayaraman T, et al. 1999. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation, 99:2164-70.
10. Goy JJ, Stauffer JC, Siegenthaler M, et al. 2005. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol, 45:308-11.
11. Gregory CR, Huang X, Pratt RE, et al. 1995. treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation, 59:655-61.
12. Groth CG, Bachman L, Morales JM, et al. 1999. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation, 67:1036-42.
13. Gruntzig AR, Senning A, Siegenthaler WE. 1979. Nonoperative dilatation of coronary-artery stenosis: percutaneous transradial coronary angioplasty. N Engl J Med, 301:61-8.
14. Hoffmann R, Guagliumi G, Musumeci G, et al. 2005. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: comparison of intravascular ultrasound results from the Multicenter, randomized E-SIRIUS, and SIRIUS trials. Catheter Cardiovasc Interv, 66:499-506.
15. Holmes DR, Jr, Teirstein P, Satler L, et al. 2006. Sirolimus-eluting stents vs vascular brachytherapy for in stent restenosis winthin bare metal stents: the SISR randomized trial. JAMA, 295:1264-73.
16. Hong MK, Park SJ, et al. 2005. American College of Cardiology Annual Scientific Sessions 2005. Oral presentation.
17. Iakovou I, Schmidt T, Bonizzoni E, et al. 2005. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 293:2126-30.
18. Jang JS, Hong MY, Lee CW, et al. 2006. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusion. J Invasive Cardiol, 18:205-8.
19. Joner M, Finn AV, Farb A, et al. 2006. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 48:193-202.
20. Kaiser C, Brunner-La Rocca HP, Buser PT, et al; BASKET Investigators. 2005. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet, 366:921-9.
21. Kastrati A, Dibra A, Eberle S, et al. 2005a. Sirolimus-eluting stents vs paclitaxel-eluting stents vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis; a randomized controlled trial. JAMA, 293:165-71.
22. Kastrati A, Dibra A, Eberle S, et al. 2005b. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA, 294:819-25.
23. Kastrati A, Dibra A, Mehilli J, et al. 2006. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation, 113:2293-300.
24. Kelbaek H, Thuesen L, Helqvist S, et al. 2006. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol, 47:449-55.
25. Kereiakes DJ, Wang H, Popma JJ, et al. 2006. Periprocedural and late consequences of overlapping cypher sirolimus-eluting stents. J Am Coll Cardiol, 48:21-31.
26. Lee JH, Kim HS, Lee SW, et al. 2006. Prospective Randomized Trial of SES vs. PES for the Treatment of Acute ST-Elevation Myocardial Infarction. American College of Cardiology Annual Scientific Sessions 2006: Late Breaking Trial Presentation.
27. Lotan C, Almagor Y, Kuiper K, et al. 2006. Sirolimus-Eluting Stent in Chronic Total Occlusion: The SICTO Study. J Interv Cardiol, 19:307-12.
28. Marx SO, Jayarman T, Go LO, et al. 1995. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res, 76:412-7.
29. Mauri L, Orav EJ, Kuntz RF. 2005. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation, 111:3435-42.
30. Mehilli J, Dibra A, Kastrati A, et al. 2006. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J, 27:260-6.
31. Meier B, Sousa E, Guagliumi G, et al. 2006. Sirolimus-eluting stents in small vessels. Am Heart J, 151:1019-27.
32. Moreno R, Fernandez C, Hernandez R, et al. 2005. Drug-Eluting Stent Thrombosis: Results From a Pooled Analysis Including 10 Randomised Studies. J Am Coll Cardiol, 45:954-9.
33. Morice MC, Serruys PW, Sousa JE, et al. 2002. The RAVEL study: a randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med, 346:1773-80.
34. Morice MC, Colombo A, Meier B, et al. 2006. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA, 295:895-904.
35. Moses JW, Leon MB, Popma JJ, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 349:1315-23.
36. Munoz JS, Abizaid A, Mintz GS, et al. 2004. Intravascular ultrasound study of effects of overlapping sirolimus-eluting stents. Am J Cardiol, 93:470-3.
37. Ortolani P, Ardissino D, Cavallini C, et al. 2005. Effect of sirolimus-eluting stents in diabetic patients with small coronary arteries (A SES-SMART sub-study). Am J Cardiol, 96:1393-8.
38. Park D-W, Park S-W, Park K-H, et al. 2006. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol, 98:352-6.
39. Pan M, Suarez de Lezo J, Medina A, et al. 2007. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J, 53:15.e1-7.
40. Pham SM, Shears LL, Kawaharda N, et al. 1998. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. Transplant Proc, 30:953-4.
41. Poon M, Marx SO, Gallo R, et al. 1996. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest, 98:2777-83.
42. Poston RS, Billingham M, Hoyt EG, et al. 1999. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation, 100:67-74.
43. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. 2005. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-elutin stent (DIABTETES) trial. Circulation, 112:2175-83.
44. Schofer J, Schluter M, Gershlick AH, et al. 2003. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet, 362:1093-9.
45. Schampaert E, Cohen EA, Schluter M, et al. 2004. The Canadian Study of the Sirolimus-eluting Stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol, 43:1110-15.
46. Schampaert E, Moses JW, Schofer J, et al. 2006. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol, 98(1):36-41.
47. Scott NA. 2006. Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev, 58:358-76.
48. Sehgal SN, Naker H, Vezina C. 1975. Rapamycin (AY-22, 989), a new antifungal antibiotic. II Fermentation, isolation and characterization. J Antibiot (Tokyo), 28:727-32.
49. Serruys PW, de Jaegere P, Kiemeneiji F, et al. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Stusy Group. N Engl J Med, 331:489-95.
50. Serruys PW, Ong A, Morice MC, et al. 2005. Arterial Revascularization Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroInterv, 2:147-56.
51. Singh K, Sun S, Vezina C. 1979. Rapamycin (AY-22, 989), a new antifungal antibiotic. IV. Mechanism of action. J Antibiot (Tokyo), 32:620-45.
52. Sousa JE, Costa MA, Abizaid AC, et al. 2001. Lack of neointimal proliferation after implantation of sirolimus coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation, 103:192-5.
53. Sousa JE, Costa MA, Abizaid A, et al. 2005. Late four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation, 111:2326-9.
54. Spier E, Huang ES, Modali R, et al. 1995. Interaction of human cytomegalovirus with p53: possible role in coronary restenosis. Scand J Infact Dis Suppl, 99:78-91.
55. Stepkowski SM, Chen H, Daloze P, et al. 1991. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplanation, 51:22-6.
56. Suarez De Lezo J, Pan M, et al. 2005. Cordoba and Las Palmas Drug-eluting Stent Study. J Am Coll Cardiol, 45(Suppl A):75A.
57. Spaulding C, Henry P, Teiger E, et al. 2006. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med, 355:1093-104.
58. Suttorp MJ, Laarman GJ, Rahel BM, et al. 2006. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). Circulation, 114:921-8.
59. Suzuki T, Kopia G, Hayashi S, et al. 2001. Stent based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation, 104:1188-93.
60. Urban P, Gershlick AH, Guagliumi G, et al. 2006. Safety of coronary sirolimus-eluting stents in daily practice: one-year follow-up of the e-CYPHER registry. Circulation, 113:1434-41.
61. Van Hout BA, van der Woude T, de Jaegere PP, et al. 1996. Cost-effectiveness of stent implantation versus PTCA: the BENESTENT experience. Semin Interv Cardiol, 1:263-8.
62. Vezina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy pf the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo), 28:721-6.
63. Weisz G, Leon MB, Holmes Dr Jr, et al. 2006. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol, 47:1350-5.
64. Windecker S, Remondino A, Eberli FR, et al. 2005. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med, 353:653-62.